Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort

Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer

(2011) L. C. Collins et al.   BREAST CANCER RESEARCH AND TREATMENT

Early onset HER2-positive breast cancer is associated with germlineTP53mutations

(2011) Amal Melhem-Bertrandt et al.   CANCER

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Population-Based Estimate of the Contribution ofTP53Mutations to Subgroups of Early-Onset Breast Cancer: Australian Breast Cancer Family Study: Table 1.

(2010) Judy Mouchawar et al.   CANCER RESEARCH

A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations

(2010) J. R. F. Wilson et al.   JOURNAL OF MEDICAL GENETICS

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   Journal of Oncology Practice

High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors

(2009) E. Manie et al.   CANCER RESEARCH

2009 Version of the Chompret Criteria for Li Fraumeni Syndrome

(2009) Julie Tinat et al.   JOURNAL OF CLINICAL ONCOLOGY

Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families Withp53Germline Mutations

(2009) Kelly D. Gonzalez et al.   JOURNAL OF CLINICAL ONCOLOGY